Coronary Artery Disease: Pathophysiology, Pharmacotherapy, Prevention and Clinical Management: BAPA

October 12, 2024

Target Audience

All pharmacists

Learning Objectives

 

At the completion of the activity viewers will be able to:

Define coronary artery disease and explain its pathophysiological mechanisms,
including the role of atherosclerosis, inflammation, and endothelial dysfunction.
Identify key modifiable and non-modifiable risk factors, such as hypertension,
hyperlipidemia, smoking, diabetes, family history, and age.
Describe the role of pharmacologic and non-pharmacologic interventions in
modifying these risk factors to prevent disease progression.
Discuss the pharmacologic classes commonly used in CAD management,
including antiplatelet agents, statins, beta-blockers, ACE inhibitors/ARBs, and
nitrates.
Examine the role of new and emerging therapies, such as PCSK9 inhibitors and
novel antithrombotic agents, in managing CAD and reducing major adverse
cardiovascular events.
Recognize the unique challenges in managing coronary artery disease in
different ethnic populations- Bangladeshi, Indian, Hispanic, and Black
populations in New York.
Analyze case studies where the optimization of pharmacotherapy, including drug
selection and dose adjustments, is critical to managing CAD in high-risk patients.
Review current evidence on the use of combination therapy, including dual
antiplatelet therapy (DAPT).
Integrate lifestyle modification strategies such as dietary changes, physical
activity, and smoking cessation into CAD management plans, emphasizing their
role in primary and secondary prevention.
Discuss the pharmacist's role in medication adherence, patient counseling, and
identifying drug-drug interactions in patients with CAD.
Evaluate the role of cardiovascular rehabilitation programs, including their impact
on long-term outcomes, quality of life, and secondary prevention of
cardiovascular events.
Understand the role of pharmacists in collaborating with cardiologists, primary
care providers, and other members of the healthcare team to ensure
comprehensive care for patients with CAD.
Promote the importance of collaborative care in reducing hospital readmissions
and improving long-term patient outcomes through coordinated care and
continuous follow-up.

Course summary
Available credit: 
  • 3.00 ACPE
    The Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Course opens: 
09/30/2024
Course expires: 
11/14/2025
Event starts: 
10/12/2024 - 9:00am EDT
Event ends: 
10/12/2024 - 12:00pm EDT
Cost:
$0.00
Rating: 
0
NY
United States

 

 

Presenter: Dr. Kazi Anam, M.S. RPh FASCP ND CH CI

 

 

 

 

 

 

ACPE UAN # 0042-9999-24-069-L01-P

 

 

Available Credit

  • 3.00 ACPE
    The Arnold & Marie Schwartz College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Price

Cost:
$0.00
Please login or register to take this course.